ReviewWorld journal of microbiology & biotechnology2026
Klebsiella pneumoniae in the global AMR: resistance mechanisms and genomic adaptation.
Review in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial Resistance (AMR) represents a defining crisis of modern healthcare, severely limiting therapeutic options and driving a global increase in clinical mortality. Central to this crisis is Klebsiella pneumoniae, a ubiquitous gut commensal that has evolved into a formidable opportunistic pathogen through its remarkable ability to transition from a harmless organism to a hypervirulent, Multidrug-Resistant (MDR) threat. This review examines that pathogenic transition, emphasizing the dangerous convergence of virulence and resistance traits particularly within carbapenem-resistant lineages. The bacterium leverages an expansive “open” pangenome and immense genetic plasticity to act as a primary trafficker of AMR genes. We detail the molecular mechanisms underlying resistance across nearly all antibiotic classes including β-lactams, aminoglycosides, and last-resort polymyxins driven by enzymatic degradation, target modification, and sophisticated efflux systems. Beyond clinical antibiotic pressure, the review explores how non-antibiotic drivers, such as environmental stressors, biocide exposure, and heavy metals, accelerate AMR evolution through cross-resistance and novel epigenetic adaptations. The rapid dissemination of these resistance determinants is facilitated by a robust toolkit of Horizontal Gene Transfer (HGT), including transposons, integrons, plasmid replicons, and bacteriophage-mediated transduction. Finally, this review evaluates the current therapeutic landscape, addressing the challenges of the drug development pipeline while highlighting emerging interventions such as novel β-lactam/β-lactamase inhibitor combinations, phage therapy, and anti-virulence strategies. Understanding this interplay between genomic evolution and ecological drivers is critical for designing a unified stewardship framework and effective interventions to curb the global AMR crisis.
Indexed as
Identifiers
41998453What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.